Generics 9

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Anagrelide manufacturers

9 products found

Filters

9 products found

anagrelide

Tablets 0.5mg, 1mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #17195
It is a pharmaceutical firm based in Central Europe that has spent the last ten years focusing on the development, production, and distribution of specialty medications. Good Manufacturing Practices and Good Distribution Practices are met by the medications. Bioequivalence and bioavailability tests have validated the medications' safety and efficacy.

Manufacturer usually replies in 7 days

anagrelide

Capsules 0.5 mg, 1 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #276
This company is a global manufacturer and distributor of high-quality generic medicines, with a mission to make these medicines accessible to patients worldwide. It operates in several regions, including Europe and Latin America, and emphasizes strong partnerships within the pharmaceutical industry to expand its reach. The company is committed to sustainability and transparency, following Environmental, Social, and Governance (ESG) principles. They regularly engage in major industry events, highlighting their dedication to networking and maintaining a leading position in the market for generic medications.

Manufacturer usually replies in 6 days

anagrelide

Capsules 0.5 mg, 1 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #313

A pharmaceutical manufacturer based in the EU that has been active in 50+ countries selling its products in Europe, North America, LATAM, and Asia for 10+ years. Key production lines are Rx, OTC, and nutraceuticals. Main therapeutic areas include the respiratory system, dermatology, and cardiovascular system. The company possesses several branches in LATAM

Manufacturer usually replies in 7 days

Want to see all 9 products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Anagrelide

Anagrelide is a drug used for the treatment of essential thrombocytosis or a condition in which the body overproduces blood platelets. Anagrelide use decreases the number of platelets cells needed to control bleeding, in patients suffering from bone marrow disorder. In this disease, body makes too much of one or other types of blood cells, such as essential thrombocythemia or polycythemia vera. While it is not chemotherapy, some of the hospitals classify it as chemotherapy as it can interfere with cell development, and the prescribing regulations similar to those governing a chemotherapy drug.
Anagrelide is especially recommended when the normal course of medication hasn’t worked, the patient has a history of Thrombosis, age above 60 and has a platelet count lower than 1000X109/L.
Anagrelide is commonly sold as Agrylin/Xagrid, Shire and Thromboreductin.
Takeda Pharma in USA first filed for a patent to manufacture Anagrelide (AGRYLIN) in 1997. Anagrelide, in its oral form, imidazoquinazoline was first approved for use in the US in 1997 and later approved for production in 1998. Anagrelide controlled release is currently in the third phase of clinical trials by Galena Biopharma for the treatment of essential thrombocytosis.

Dosage and forms

Anagrelide is sold in the form of a capsule. It is taken orally. The starting adult dose of Anagrelide is 0.5 mg which can be increased to 1 mg. the daily maximum dose limited at 2.5 mg. normally the patients will experience good responses at a median dose of 2-2.5 mg/day. As the medication is taken over time, the body should witness the platelet counts begin to decrease within 7-10 days of starting the course.

Cost of Anagrelide

In the USA, the consumer on an average have to pay USD 273 for a pack of 100 tablets with prescription-strength of 500mg, whereas the same supply costs significantly higher at 404 pounds in the UK. In the developing world, it costs USD 235, slightly cheaper than in the USA. However, the prices in the USA can vary depending on the insurance and discounts being offered to people on the different program in order to reduce the overall cost of the treatment.

How does Anagrelide work?

Anagrelide works by inhibiting the maturation of platelets from megakaryocytes. The exact mechanism of action is unclear, although it is known to be a phosphodiesterase inhibitor. Anagrelide is in a class of drugs named platelet-reducing agents. These agents work by slowing the production of platelets in the body. But it is hypothesized that Anagrelide selectively suppresses bone marrow megakaryocytes by interfering with the maturation process thus decreasing platelet production.

Finding Anagrelide Manufacturers and Suppliers

The process of finding trusted Anagrelide manufacturers and Anagrelide suppliers can be made quicker and more accessible by using Pipelinepharma's online platform, a B2B a marketplace that lets you finalize the deals of pharmaceutical products in a matter of a few clicks. Also, it is an easy to use online platform to grow your business opportunities.
The robust search engine makes it convenient to search for manufacturers and suppliers of Anagrelide. The search can be further refined with industry-specific filters such as dossier type, country of origin, GMP approvals, and search criteria for Wholesaler, etc. helping to get in contact with the preferred manufacturer and supplier readily.

Interested in becoming a subscriber?

Please provide the following information to receive an offer tailored to your business needs

  1. Number of company users for the subscription
  2. The rough number of products you would like to source in the 12 months
  3. Target market(s) for commercialisation